PT  - JOURNAL ARTICLE
AU  - van der Pal, Zarah
AU  - Walhovd, Kristine B
AU  - Amlien, Inge K
AU  - Guichelaar, Carlijn Jamila
AU  - Kaiser, Antonia
AU  - Bottelier, Marco A
AU  - Geurts, Hilde M
AU  - Reneman, Liesbeth
AU  - Schrantee, Anouk
TI  - Stimulant medication use and apparent cortical thickness development in attention-deficit/hyperactivity disorder: a prospective longitudinal study
AID  - 10.1101/2023.07.28.23293202
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.07.28.23293202
4099  - http://medrxiv.org/content/early/2023/07/31/2023.07.28.23293202.short
4100  - http://medrxiv.org/content/early/2023/07/31/2023.07.28.23293202.full
AB  - Background Stimulant medication is commonly prescribed as treatment for attention-deficit/hyperactivity disorder (ADHD). While we previously found that short-term stimulant-treatment influences apparent cortical thickness development in an age-dependent manner, it remains unknown whether these effects persist throughout development into adulthood.Purpose Investigate the long-term age-dependent effects of stimulant medication on apparent cortical thickness development in adolescents and adults previously diagnosed with ADHD.Methods This prospective study included the baseline and 4-year follow-up assessment of the “effects of Psychotropic drugs On the Developing brain-MPH” (“ePOD-MPH”) project, conducted between June-1-2011 and December-28-2019. The analyses were pre-registered (https://doi.org/10.17605/OSF.IO/32BHF). T1-weighted MR scans were obtained from male adolescents and adults, and cortical thickness was estimated for predefined regions of interest (ROIs) using Freesurfer. We determined medication use and assessed symptoms of ADHD, anxiety, and depression at both time points. Linear mixed models were constructed to assess main effects and interactions of stimulant medication use, time, and age group on regional apparent cortical thickness.Results A total of 32 male adolescents (aged mean±SD, 11.2±0.9 at baseline) and 24 men (aged mean±SD, 29.9±5.0 at baseline) were included that previously participated in the ePOD-MPH project. We found no evidence for long-term effects of stimulant medication use on ROI apparent cortical thickness. As expected, we did find age-by-time interaction effects in all ROIs (left prefrontal ROI: P=.002, right medial and posterior ROIs: P<.001), reflecting reductions in apparent cortical thickness in adolescents. Additionally, ADHD symptom severity (adolescents: P<.001, adults: P=.001) and anxiety symptoms (adolescents: P=0.03) were reduced, and lower change in ADHD symptoms was associated with higher medication use in adults (P=0.001).Conclusion We found no evidence for long-term effects of stimulant-treatment for ADHD on apparent cortical thickness development in adolescents and adults. The identified age-dependent differences in apparent cortical thickness development are consistent with existing literature on typical cortical development.Summary statement This prospective longitudinal study in male adolescents and adults found that stimulant medication does not modulate long-term apparent cortical thickness development.Key resultsIn this prospective longitudinal structural MRI study of 32 male adolescents and 24 men previously diagnosed with attention-deficit/hyperactivity disorder (ADHD), we found no evidence for long-term effects of stimulant medication on apparent cortical thickness development.We identified age-dependent patterns of cortical development, with reductions in apparent cortical thickness in adolescents only (P<.001 in all regions of interest).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe Netherlands National Trial Register (identifier NTR3103)Funding StatementThis study was funded by the Dutch non-profit organizations Kiddy GoodPills and Suffigium. The ePOD-MPH RCT (baseline data) was funded by a personal research grant awarded to LR by the Academic Medical Center, University of Amsterdam, and 11.32050.26ERA-NET PRIOMEDCHILD FP 6(EU).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of the Central Committee on Research Involving Human Subjects, The Netherlands, and of the Academic Medical Center, Amsterdam, The Netherlands gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.AbbreviationsADHDattention-deficit/hyperactivity disorderePOD-MPHeffects of Psychotropic drugs On the Developing brain - methylphenidateMPHmethylphenidateRCTrandomised controlled trialROIregion of interest